NASDAQ:NKTR - Nektar Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.83
  • Forecasted Upside: 135.92 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.83 (-7.05%)

This chart shows the closing price for NKTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

Analyst Price Target is $25.83
▲ +135.92% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $25.83, with a high forecast of $54.00 and a low forecast of $18.00. The average price target represents a 135.92% upside from the last price of $10.95.

This chart shows the closing price for NKTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Nektar Therapeutics. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2021BTIG ResearchLower Price TargetPositive ➝ Buy$80.00 ➝ $54.00High
11/8/2021SVB LeerinkLower Price TargetMarket Perform$19.00 ➝ $18.00High
11/8/2021BenchmarkUpgradeHold ➝ Buy$20.00High
11/5/2021OppenheimerLower Price TargetMarket Perform$25.00 ➝ $21.00High
9/10/2021Bank of AmericaInitiated CoverageNeutral$18.00Low
8/6/2021SVB LeerinkLower Price TargetMarket Perform$20.00 ➝ $19.00Low
6/28/2021Stifel NicolausUpgradeHold ➝ Buy$22.00 ➝ $24.00Medium
5/10/2021SVB LeerinkLower Price TargetMarket Perform$21.00 ➝ $20.00Low
5/7/2021MizuhoReiterated RatingBuyHigh
4/6/2021SVB LeerinkBoost Price TargetMarket Perform$20.00 ➝ $21.00Low
3/1/2021BenchmarkReiterated RatingBuy ➝ Hold$26.00Low
2/22/2021BenchmarkDowngradeBuy ➝ Hold$26.00High
1/5/2021Stifel NicolausInitiated CoverageHold$18.00N/A
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $20.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral$26.00High
8/14/2020SVB LeerinkLower Price TargetMarket Perform$18.00 ➝ $17.00Medium
8/7/2020OppenheimerReiterated RatingHold$25.00High
6/10/2020CfraDowngradeHold ➝ SellLow
5/26/2020MizuhoInitiated CoverageBuy$35.00Low
5/18/2020OppenheimerBoost Price TargetMarket Perform$24.00 ➝ $25.00Medium
5/12/2020HC WainwrightLower Price TargetNeutral$32.00 ➝ $26.00High
5/8/2020SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $18.00High
4/22/2020BenchmarkInitiated CoverageBuy$26.00Medium
4/2/2020MizuhoReiterated RatingBuy$35.00High
3/30/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$18.00 ➝ $20.00Low
3/9/2020JPMorgan Chase & Co.Lower Price TargetNeutral$28.00 ➝ $27.00High
3/4/2020BarclaysInitiated CoverageOverweight$30.00High
2/28/2020Piper SandlerReiterated RatingBuy$35.00High
2/28/2020BTIG ResearchLower Price TargetBuy$101.00 ➝ $80.00High
2/28/2020William BlairReiterated RatingOutperformHigh
2/28/2020CowenReiterated RatingBuy$27.00Low
2/12/2020CowenReiterated RatingBuy$30.00Medium
2/3/2020MizuhoReiterated RatingNeutral ➝ Buy$21.00 ➝ $35.00High
1/10/2020MizuhoInitiated CoverageHold$21.00High
1/10/2020HC WainwrightReiterated RatingHold$32.00High
11/11/2019HC WainwrightBoost Price TargetNeutral$24.00 ➝ $32.00High
11/7/2019Piper Jaffray CompaniesLower Price TargetOverweight$50.00 ➝ $35.00High
11/7/2019CowenReiterated RatingBuyHigh
11/7/2019MizuhoReiterated RatingHold$21.00High
10/24/2019OppenheimerInitiated CoverageMarket Perform$18.00Medium
10/8/2019The Goldman Sachs GroupDowngradeBuy ➝ Sell$54.00 ➝ $16.00High
9/30/2019HC WainwrightSet Price TargetHold$24.00High
9/26/2019CowenSet Price TargetBuy$43.00Medium
9/26/2019William BlairReiterated RatingBuyMedium
9/26/2019Piper Jaffray CompaniesSet Price TargetBuy$50.00Medium
8/13/2019HC WainwrightReiterated RatingHoldMedium
8/11/2019Evercore ISIReiterated RatingHold$37.00High
8/9/2019William BlairReiterated RatingBuyLow
8/9/2019CfraSet Price TargetHold$35.00Low
8/9/2019BMO Capital MarketsLower Price TargetOutperform$75.00 ➝ $41.00High
8/9/2019MizuhoDowngradeBuy ➝ Neutral$79.00 ➝ $21.00High
8/9/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$62.00 ➝ $33.00High
8/9/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $23.00High
8/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $100.00High
7/26/2019MizuhoLower Price TargetBuy$81.00 ➝ $79.00High
6/14/2019William BlairReiterated RatingBuyMedium
6/13/2019CowenSet Price TargetBuy$82.00Medium
6/4/2019William BlairReiterated RatingBuyMedium
6/2/2019CowenSet Price TargetBuy$82.00High
5/24/2019MizuhoReiterated RatingBuy$81.00Low
3/15/2019SVB LeerinkInitiated CoverageMkt Perform$38.00Medium
3/4/2019HC WainwrightReiterated RatingHold$47.00Low
3/1/2019Piper Jaffray CompaniesSet Price TargetBuy$100.00Low
3/1/2019MizuhoReiterated RatingBuy$81.00High
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$75.00Medium
2/19/2019MizuhoReiterated RatingBuyLow
2/19/2019HC WainwrightReiterated RatingHold$47.00Low
1/23/2019MizuhoReiterated RatingBuy$81.00 ➝ $81.00Low
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Buy$81.00 ➝ $62.00High
11/12/2018HC WainwrightSet Price TargetHold$47.00High
11/8/2018CowenReiterated RatingBuy$86.00High
11/8/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$103.00 ➝ $73.00High
11/5/2018HC WainwrightReiterated RatingHold$47.00Medium
10/22/2018HC WainwrightSet Price TargetHold$54.00High
8/10/2018HC WainwrightSet Price TargetHold$54.00Medium
8/9/2018William BlairReiterated RatingOutperformHigh
8/9/2018CowenReiterated RatingBuy$86.00High
8/9/2018MizuhoReiterated RatingBuy$103.00High
8/8/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
7/31/2018HC WainwrightReiterated RatingHold$54.00Low
7/25/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
6/11/2018HC WainwrightDowngradeBuy ➝ Neutral$54.00Low
6/4/2018William BlairReiterated RatingBuyHigh
6/4/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$90.00 ➝ $78.00High
6/4/2018HC WainwrightLower Price TargetBuy$97.00High
5/20/2018HC WainwrightSet Price TargetBuy$125.00Low
5/14/2018HC WainwrightSet Price TargetBuy$125.00Medium
5/11/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
4/30/2018HC WainwrightSet Price TargetBuy$125.00Low
4/26/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00Low
4/17/2018HC WainwrightSet Price TargetBuy$125.00Low
4/17/2018MizuhoReiterated RatingBuy$103.00Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$125.00Medium
4/9/2018HC WainwrightSet Price TargetBuy$125.00High
4/6/2018MizuhoBoost Price TargetBuy ➝ Buy$89.00 ➝ $103.00Medium
4/2/2018HC WainwrightReiterated RatingBuy ➝ Buy$125.00High
3/29/2018MizuhoSet Price TargetBuy$89.00Low
3/2/2018CowenReiterated RatingBuy$101.00Low
3/2/2018Jefferies Financial GroupBoost Price TargetBuy$103.00High
2/14/2018MizuhoReiterated RatingBuy$89.00Medium
1/22/2018MizuhoBoost Price TargetBuy ➝ Buy$45.00 ➝ $89.00High
1/16/2018Jefferies Financial GroupBoost Price TargetBuy$2.12 ➝ $88.00High
11/15/2017Canaccord Genuity GroupBoost Price TargetBuy$35.00 ➝ $50.00N/A
11/14/2017MizuhoBoost Price TargetBuy$30.00 ➝ $45.00N/A
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/A
11/13/2017JPMorgan Chase & Co.Reiterated RatingPositive ➝ Buy$44.00N/A
11/8/2017MizuhoReiterated RatingBuy ➝ Buy$30.00 ➝ $45.00N/A
11/8/2017Jefferies Financial GroupReiterated RatingBuy$35.00N/A
11/7/2017CowenInitiated CoverageOutperformN/A
9/26/2017MizuhoInitiated CoverageBuy$30.00High
8/18/2017Jefferies Financial GroupReiterated RatingBuy$23.00Low
8/17/2017Evercore ISIInitiated CoverageIn ➝ In-Line$20.00High
8/9/2017Roth CapitalSet Price TargetBuy$33.00High
8/7/2017HC WainwrightInitiated CoverageBuy ➝ Buy$31.00Low
7/21/2017Jefferies Financial GroupReiterated RatingBuy$23.00Medium
7/18/2017William BlairReiterated RatingOutperformLow
6/26/2017William BlairReiterated RatingOutperformLow
5/22/2017Roth CapitalSet Price TargetBuy$31.00Medium
5/11/2017Roth CapitalSet Price TargetBuy$31.00Low
5/10/2017Jefferies Financial GroupLower Price TargetBuy$25.00 ➝ $23.00Medium
5/10/2017AegisReiterated RatingBuy$27.00High
4/22/2017Jefferies Financial GroupSet Price TargetBuy$25.00Medium
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00Low
4/6/2017AegisBoost Price TargetBuy$24.00 ➝ $27.00Low
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 ➝ $27.00Medium
3/21/2017JPMorgan Chase & Co.Set Price TargetBuy$24.00Medium
3/21/2017Jefferies Financial GroupBoost Price TargetPositive$17.00 ➝ $25.00High
3/20/2017AegisBoost Price TargetBuy$21.00 ➝ $24.00High
3/20/2017Roth CapitalSet Price TargetBuy ➝ Buy$23.00 ➝ $31.00Medium
3/4/2017Roth CapitalSet Price TargetBuy$23.00N/A
3/3/2017Jefferies Financial GroupReiterated RatingBuy$15.00 ➝ $17.00N/A
3/2/2017AegisReiterated RatingBuy$21.00N/A
(Data available from 1/22/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Nektar Therapeutics logo
Nektar Therapeutics is a research-based biopharmaceutical company that focuses on discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and auto-immune disease. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $10.95
Low: $10.91
High: $11.90

50 Day Range

MA: $12.75
Low: $10.83
High: $15.73

52 Week Range

Now: $10.95
Low: $10.59
High: $26.75


3,641,313 shs

Average Volume

2,374,787 shs

Market Capitalization

$2.02 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: Bank of America Co., Benchmark Co., BTIG Research, Mizuho, Oppenheimer Holdings Inc., Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for NKTR.

What is the current price target for Nektar Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $25.83, suggesting a possible upside of 135.9%. BTIG Research has the highest price target set, predicting NKTR will reach $54.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $18.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.

What is the current consensus analyst rating for Nektar Therapeutics?

Nektar Therapeutics currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTR will outperform the market and that investors should add to their positions of Nektar Therapeutics.
View the latest ratings for NKTR.

What other companies compete with Nektar Therapeutics?

How do I contact Nektar Therapeutics' investor relations team?

Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 482-5300 and its investor relations email address is [email protected] The official website for Nektar Therapeutics is